• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Jim Cramer Calls This Healthcare Stock A 'Worthy Spec,' Recommends Avoiding Canada Goose

    5/21/24 8:44:19 AM ET
    $ABT
    $BROS
    $GOOS
    $MGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Restaurants
    Consumer Discretionary
    Get the next $ABT alert in real time by email

    On CNBC's “Mad Money Lightning Round,” Jim Cramer recommended buying Dutch Bros Inc. (NYSE:BROS).

    On May 7, Dutch Bros posted better-than-expected first-quarter financial results and raised its full-year revenue guidance.

    “The outlook is fabulous. There is a lawsuit in July that, involving formula,” Cramer said when asked about Abbott Laboratories (NYSE:ABT). “We're waiting until at least it gets to par or 100 to be able to buy more. But we believe in the company.”

    On April 17, Abbott Laboratories reported better-than-expected earnings for its first quarter. The company posted first-quarter sales of $9.96 billion, up 10.8% on an organic basis for the underlying base business, beating the consensus of $9.88 billion. Abbott's adjusted diluted earnings per share was 98 cents, beating the analyst estimates of 95 cents.

    Cramer commented on Canada Goose Holdings Inc. (NYSE:GOOS): “When I see a company report that kind of number that good and it doesn't go up, I say, ain't nothing going to get this thing going.”

    On May 16, Canada Goose Hold reported better-than-expected fourth-quarter FY24 earnings. The company reported fourth-quarter sales growth of 22% year-on-year to C$358 million, beating the analyst consensus estimate of C$315.491 million.

    The “Mad Money” host said Nutanix, Inc. (NASDAQ:NTNX) is “what the market wants right now. It's enterprise software, enterprise cloud platforms. People can't get enough of it.”

    The San Jose, California-based company is expected to report its financial results for the third quarter of fiscal year 2024, after the closing bell on Wednesday, May 29.

    MeiraGTx Holdings plc (NASDAQ:MGTX) is a “worthy spec,” Cramer said, “You want to be there because it's limited downside and some nice upside.”

    On May 9, MeiraGTx posted a narrower-than-expected loss for its first quarter.

    Price Action:

    • Abbott Laboratories shares fell 0.9% to settle at $103.21 on Monday.
    • Nutanix shares gained 2.7% to close at $72.16
    • Dutch Bros shares gained 0.2% to settle at $36.77 on Monday.
    • Canada Goose shares fell 1.3% to settle at $13.12.
    • MeiraGTx shares fell 3% to close at $5.54 on Monday.

    Read Next: $3.5M Bet On This Healthcare Stock? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying

    Image: Shutterstock

    Get the next $ABT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABT
    $BROS
    $GOOS
    $MGTX

    CompanyDatePrice TargetRatingAnalyst
    Canada Goose Holdings Inc. Subordinate Voting Shares
    $GOOS
    2/6/2026$10.00Equal Weight → Underweight
    Barclays
    Dutch Bros Inc.
    $BROS
    1/26/2026$82.00Buy
    Citigroup
    Nutanix Inc.
    $NTNX
    1/15/2026$53.00Overweight → Equal Weight
    Barclays
    Nutanix Inc.
    $NTNX
    1/12/2026Overweight → Equal-Weight
    Morgan Stanley
    Nutanix Inc.
    $NTNX
    11/26/2025$80.00 → $65.00Buy
    Needham
    MeiraGTx Holdings plc
    $MGTX
    11/24/2025$20.00Buy
    H.C. Wainwright
    Nutanix Inc.
    $NTNX
    11/17/2025Outperform
    Oppenheimer
    Dutch Bros Inc.
    $BROS
    10/22/2025$92.00 → $65.00Overweight
    Barclays
    More analyst ratings

    $ABT
    $BROS
    $GOOS
    $MGTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canada Goose downgraded by Barclays with a new price target

    Barclays downgraded Canada Goose from Equal Weight to Underweight and set a new price target of $10.00

    2/6/26 8:06:40 AM ET
    $GOOS
    Apparel
    Consumer Discretionary

    Citigroup initiated coverage on Dutch Bros with a new price target

    Citigroup initiated coverage of Dutch Bros with a rating of Buy and set a new price target of $82.00

    1/26/26 10:01:23 AM ET
    $BROS
    Restaurants
    Consumer Discretionary

    Nutanix downgraded by Barclays with a new price target

    Barclays downgraded Nutanix from Overweight to Equal Weight and set a new price target of $53.00

    1/15/26 8:33:55 AM ET
    $NTNX
    Computer Software: Prepackaged Software
    Technology

    $ABT
    $BROS
    $GOOS
    $MGTX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    October 24, 2023 - FDA Approves New Therapy for Rare Form of Blood Cancers Called Myelodysplastic Syndromes

    For Immediate Release: October 24, 2023 Today, the U.S. Food and Drug Administration approved Tibsovo (ivosidenib) for the treatment of adult patients with relapsed or refractory (R/R) myelodysplastic syndromes (MDS) with an isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. This is the first targeted therapy approved for this indication. The agency also approved the Abbott RealTime

    10/24/23 3:52:17 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    $BROS
    $GOOS
    $MGTX
    SEC Filings

    View All

    Nutanix Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Nutanix, Inc. (0001618732) (Filer)

    2/25/26 4:12:53 PM ET
    $NTNX
    Computer Software: Prepackaged Software
    Technology

    SEC Form 424B5 filed by Abbott Laboratories

    424B5 - ABBOTT LABORATORIES (0000001800) (Filer)

    2/25/26 7:01:49 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B3 filed by Abbott Laboratories

    424B3 - ABBOTT LABORATORIES (0000001800) (Filer)

    2/23/26 9:31:03 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    $BROS
    $GOOS
    $MGTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO and President Barone Christine converted options into 6,095 shares and covered exercise/tax liability with 1,682 shares, increasing direct ownership by 10% to 46,444 units (SEC Form 4)

    4 - Dutch Bros Inc. (0001866581) (Issuer)

    2/24/26 5:53:14 PM ET
    $BROS
    Restaurants
    Consumer Discretionary

    Chief Legal Officer Tullett Victoria J converted options into 1,168 shares and covered exercise/tax liability with 376 shares, increasing direct ownership by 5% to 15,535 units (SEC Form 4)

    4 - Dutch Bros Inc. (0001866581) (Issuer)

    2/24/26 5:52:43 PM ET
    $BROS
    Restaurants
    Consumer Discretionary

    Chief Marketing Officer Davila Tana converted options into 1,523 shares and covered exercise/tax liability with 490 shares, increasing direct ownership by 8% to 13,604 units (SEC Form 4)

    4 - Dutch Bros Inc. (0001866581) (Issuer)

    2/24/26 5:52:17 PM ET
    $BROS
    Restaurants
    Consumer Discretionary

    $ABT
    $BROS
    $GOOS
    $MGTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Starks Daniel J bought $1,087,331 worth of Common shares without par value (10,000 units at $108.73), increasing direct ownership by 0.15% to 6,738,817 units (SEC Form 4)

    4 - ABBOTT LABORATORIES (0000001800) (Issuer)

    2/6/26 8:04:16 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHAIRMAN AND CEO Ford Robert B bought $2,013,967 worth of Common shares without par value (18,800 units at $107.13) (SEC Form 4)

    4 - ABBOTT LABORATORIES (0000001800) (Issuer)

    1/26/26 8:02:24 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Perceptive Advisors Llc bought $5,000,000 worth of Ordinary Shares (1,250,000 units at $4.00) (SEC Form 4)

    4 - MeiraGTx Holdings plc (0001735438) (Issuer)

    8/14/24 6:54:38 PM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABT
    $BROS
    $GOOS
    $MGTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    AMD and Nutanix Announce Strategic Partnership to Advance an Open and Scalable Platform for Enterprise AI

    News Highlights AMD and Nutanix sign multi-year agreement to accelerate adoption of Nutanix-powered agentic AI platform on AMD accelerated compute infrastructure for enterprise AI and service providers AMD to invest and fund up to $250 million in Nutanix shares, and R&D and go-to-market for integrated solutions Joint roadmap to integrate AMD ROCm™ and AMD Enterprise AI software into the Nutanix Cloud Platform and the Nutanix Kubernetes Platform using AMD EPYC™ CPUs and AMD Instinct™ GPUs with support from a broad set of OEM server providers  SANTA CLARA, Calif. and SAN JOSE, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- AMD (NASDAQ:AMD) and Nutanix (NASDAQ:NTNX) today announced a multi-year

    2/25/26 4:11:00 PM ET
    $AMD
    $NTNX
    Semiconductors
    Technology
    Computer Software: Prepackaged Software

    Nutanix Reports Second Quarter Fiscal 2026 Financial Results

    SAN JOSE, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Nutanix, Inc. (NASDAQ:NTNX), a leader in hybrid multicloud computing, today announced financial results for its second quarter ended January 31, 2026. "Our business performed solidly in the second quarter, including strong bookings, strong new logo additions, and solid free cash flow performance," said Rajiv Ramaswami, CEO of Nutanix. "Our opportunities with AI, modern applications, hybrid multicloud, and support for external storage provide us with a strong foundation for multi-year growth." "We saw healthy demand in our second quarter, as reflected in results that exceeded the high end of the range for all of our guided metrics. Howev

    2/25/26 4:01:00 PM ET
    $NTNX
    Computer Software: Prepackaged Software
    Technology

    Canada Goose Announces Participation in 47th Raymond James Institutional Investor Conference

    Canada Goose Holdings Inc. ((NYSE, TSX:GOOS) today announced that it will participate in the 47th Raymond James Institutional Investor Conference being held at the JW Marriott Grande Lakes, Orlando, Florida on March 2, 2026. We will host a fireside chat presentation at 4 pm ET and participate in one-on-one meetings. Neil Bowden, Chief Financial Officer will attend the conference. The fireside chat presentation will be webcast live on our investor relations website, http://investor.canadagoose.com. An archived webcast will be available after the conclusion of the presentation. About Canada Goose Canada Goose is dedicated to empowering discovery and pushing boundaries in design, functio

    2/23/26 7:00:00 AM ET
    $GOOS
    Apparel
    Consumer Discretionary

    $ABT
    $BROS
    $GOOS
    $MGTX
    Leadership Updates

    Live Leadership Updates

    View All

    Canada Goose Appoints Patrick Bourke as President, North America

    Canada Goose Holdings Inc. (NYSE:GOOS, TSX:GOOS) today announced the appointment of Patrick Bourke as President, North America, effective February 5, 2026. Bourke will oversee the brand's North American business with responsibility for driving brand momentum, strengthening retail and wholesale execution, and deepening consumer connections across the region. He will partner closely with the global leadership team to advance the company's operating imperatives, with a focus on brand heat, strategic channel expansion, and operating with pace and accountability. "Patrick is an action‑oriented, high‑energy leader with a strong track record of delivering results," said Dani Reiss, Chairman & CE

    2/5/26 6:50:00 AM ET
    $GOOS
    Apparel
    Consumer Discretionary

    TTM Technologies, Dutch Bros, Advanced Energy Industries, and American Healthcare REIT Set to Join S&P MidCap 400; Others to Join S&P SmallCap 600

    NEW YORK, Jan. 27, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400, S&P SmallCap 600: S&P SmallCap 600 constituent TTM Technologies Inc. (NASD: TTMI) will replace Civitas Resources Inc. (NYSE:CIVI) in the S&P MidCap 400, and Amneal Pharmaceuticals Inc. (NASD: AMRX) will replace TTM Technologies in the S&P SmallCap 600 effective prior to the opening of trading on Friday, January 30. S&P SmallCap 600 constituent SM Energy Co. (NYSE:SM) is acquiring Civitas Resources in a deal expected to be completed soon, pending final closing conditions. SM Energy will remain in the S&P SmallCap 600 post-merger.Dutch Bros Inc. (NYSE:BROS) will replace Potlatc

    1/27/26 6:02:00 PM ET
    $AEIS
    $AHR
    $AMRX
    Industrial Machinery/Components
    Technology
    Real Estate Investment Trusts
    Real Estate

    Dutch Bros Inc. Appoints Jennifer Somers as Chief Shops Officer

    Dutch Bros Inc. (NYSE:BROS, "Dutch Bros" or the "Company")), one of the fastest-growing brands in the U.S. quick-service beverage industry, today announced the appointment of Jennifer Somers as Chief Shops Officer. Reporting to Christine Barone, Chief Executive Officer and President of Dutch Bros, Somers will lead Dutch Bros' field organization and shop operations, overseeing operational excellence, growth, and consistent brand execution across company-owned and franchise shop locations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260105673040/en/Jennifer Somers, Chief Shops Officer of Dutch Bros "Jennifer is a people-first l

    1/5/26 4:05:00 PM ET
    $BROS
    Restaurants
    Consumer Discretionary

    $ABT
    $BROS
    $GOOS
    $MGTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Dutch Bros Inc.

    SC 13G/A - Dutch Bros Inc. (0001866581) (Subject)

    11/14/24 4:21:31 PM ET
    $BROS
    Restaurants
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Dutch Bros Inc.

    SC 13G/A - Dutch Bros Inc. (0001866581) (Subject)

    11/14/24 1:28:34 PM ET
    $BROS
    Restaurants
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Canada Goose Holdings Inc. Subordinate Voting Shares

    SC 13G/A - Canada Goose Holdings Inc. (0001690511) (Subject)

    11/14/24 12:31:28 PM ET
    $GOOS
    Apparel
    Consumer Discretionary

    $ABT
    $BROS
    $GOOS
    $MGTX
    Financials

    Live finance-specific insights

    View All

    Nutanix Reports Second Quarter Fiscal 2026 Financial Results

    SAN JOSE, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Nutanix, Inc. (NASDAQ:NTNX), a leader in hybrid multicloud computing, today announced financial results for its second quarter ended January 31, 2026. "Our business performed solidly in the second quarter, including strong bookings, strong new logo additions, and solid free cash flow performance," said Rajiv Ramaswami, CEO of Nutanix. "Our opportunities with AI, modern applications, hybrid multicloud, and support for external storage provide us with a strong foundation for multi-year growth." "We saw healthy demand in our second quarter, as reflected in results that exceeded the high end of the range for all of our guided metrics. Howev

    2/25/26 4:01:00 PM ET
    $NTNX
    Computer Software: Prepackaged Software
    Technology

    Abbott declares 409th consecutive quarterly dividend

    ABBOTT PARK, Ill., Feb. 20, 2026 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 63 cents per share. This marks the 409th consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable May 15, 2026, to shareholders of record at the close of business on April 15, 2026.Abbott has increased its dividend payout for 54 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have increased dividends annually for at least 25 consecutive years.About Abbott:Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio o

    2/20/26 11:38:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A

    AUSTIN, Texas, Feb. 17, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Biotech dealmaking is increasingly defined by a clear strategic shift: Pharmaceutical companies are prioritizing de-risked, late-stage assets with human clinical validation rather than speculative early-stage programs. After years of capital flowing into preclinical platforms with uncertain timelines, investors and acquirers are gravitating toward programs with established safety and efficacy data that can accelerate commercialization pathways. This evolving landscape naturally places companies such as Oncotelic Therapeutics Inc. (OTCQB:OTLC) (profile), which holds multiple clinical-stage and late-stage program

    2/17/26 8:30:00 AM ET
    $ARWR
    $JNJ
    $MGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)